Human Genetic Host Factors and Its Role in the Pathogenesis of Chikungunya Virus Infection

Juan C. Rueda1,2, Mauricio Arcos-Burgos3, Ana M. Santos2, Daniel Martin-Arsanios2, Catalina Villota-Erazo2,4, Viviana Reyes2,4, Santiago Bernal-Macías2,4, Ingris Peláez-Ballestas5, Mario H. Cardiel6 and John Londono2,4*

1 Faculty of Medicine and Engineering, Universidad de La Sabana, Chía, Colombia, 2 Grupo de Espondiloartropatías, Rheumatology Department, Universidad de La Sabana, Chía, Colombia, 3 Grupo de Investigación en Psiquiatría (GIPS), Departamento de Psiquiatría, Faculty of Medicine, Instituto de Investigaciones Médicas, Universidad de Antioquia, Medellín, Colombia, 4 Rheumatology Department, Hospital Militar Central, Bogotá, Colombia, 5 Rheumatology Unit, Hospital General de México “Doctor Eduardo Liceaga”, Mexico City, Mexico, 6 Centro de Investigación Clínica de Morelia, Morelia, SC, Mexico

Chikungunya virus (CHIKV) is an alphavirus from the Togaviridae family that causes acute arthropathy in humans. It is an arthropod-borne virus transmitted initially by the Aedes (Ae) aegypti and after 2006’s epidemic in La Reunion by Ae albopictus due to an adaptive mutation of alanine for valine in the position 226 of the E1 glycoprotein genome (A226V). The first isolated cases of CHIKV were reported in Tanzania, however since its arrival to the Western Hemisphere in 2013, the infection became a pandemic. After a mosquito bite from an infected viremic patient the virus replicates eliciting viremia, fever, rash, myalgia, arthralgia, and arthritis. After the acute phase, CHIKV infection can progress to a chronic stage where rheumatic symptoms can last for several months to years. Although there is a great number of studies on the pathogenesis of CHIKV infection not only in humans but also in animal models, there still gaps in the proper understanding of the disease. To this date, it is unknown why a percentage of patients do not develop clinical symptoms despite having been exposed to the virus and developing an adaptive immune response. Also, controversy stills exist on the pathogenesis of chronic joint symptoms. It is known that host immune response to an infectious disease is reflected on patient’s symptoms. At the same time, it is now well-established that host genetic variation is an important component of the varied onset, severity, and outcome of infectious disease. It is essential to understand the interaction between the aetiological agent and the host to know the chronic sequelae of the disease. The present review summarizes the current findings on human host genetics and its relationship with immune response in CHIKV infection.

Keywords: chikungunya, genetic, host, pathogenesis, arbovirus

INTRODUCTION

Chikungunya virus (CHIKV) is an alphavirus from the Togaviridae family, and a member of the Semliki Forest virus antigenic complex, that together with other alphaviruses (O’nyong-nyong, Mayaro, and Ross River) causes acute arthropathy in humans (1–3). The virion has an icosahedral capsid, enclosed by a lipid envelope with a single-stranded, positive sense, RNA genome of...
~12 kilobases in length, which is arranged in two open reading frames (ORF) with a junction region in between (4, 5). The 5′ ORF contains code for four non-structural proteins (nsP1-4), whereas the 3′ encodes the capsid protein (C), two surface envelope glycoproteins (E1 and E2), and two small peptides designated E3 and 6k (6, 7).

A mosquito bite from an infected viremic patient is where the transmission initially starts (8). The virus replicates for a few days, before being transmitted to another person (9). Upon mosquito bite, the virus due to cellular tropism, infects fibroblasts in the dermis and macrophages, following an incubation period of 3–7 days, from where it is disseminated through lymphatics and bloodstream to joint capsule, muscle, epithelial, and endothelial cells (8). The virus replicates eliciting viremia, fever, rash, myalgia, arthralgia and arthritis (10). At this point the acute phase is established, lasting for ~2 weeks, and again evolving into a new lineage with the aforementioned Asian lineage (7). From here on, transmission from human to human via Ae albopictus as a new vector is known today as Tanzania (17). The people of this region named the disease chikungunya, which translates to “the one that bends up the joints” (18). Phylogenetic studies indicated that CHIKV originated in Africa over 500 years ago and determined that a common lineage diverged into two branches termed West African (WA) and East/Central/South African (ECSA) (1, 2, 19, 20). While the ECSA lineage spread outside Africa causing multiple urban epidemics in Asia almost 150 years ago, WA lineage maintained local outbreaks in Africa through enzootic transmission (8, 20). It was in Asia were the ECSA lineage kept circulating and evolving into a separate genotype called Asian lineage (20). In the early 2000, the ECSA lineage reached Kenya and from there expanded to islands in the Indian Ocean, India, and Southeast Asia creating an unprecedented epidemic and again evolving into a new lineage with the aforementioned A226V mutation (Indian Ocean Lineage or IOL) (15, 21–23). This allowed the virus to use Ae albopictus as a new vector which has a higher altitude tolerance and therefore increasing the disease’s reach to more temperate regions like southern France and northern Italy (24–27). During the last decade CHIKV continued to cause epidemics in the Pacific Islands, Indian subcontinent, Oceania and Southeast Asia (28–30). Finally, in 2013 the CHIKV Asian lineage arrived to the Western Hemisphere with the first autochthonous cases reported in the Island of Saint Martin (31). From there, the virus rapidly spread throughout the Caribbean, Central and South America, affecting 42 countries by 2015 (32). The virus kept circulating mainly in Asia and the Americas with outbreaks being continuously reported. In Brazil for example, 712,990 cases were accumulated over a period of 4 years since 2015 (33). In the years 2016, 2017 and 2019, a maximum number of laboratory confirmed cases were reported in India (34). Also, the first large epidemic in Pakistan was reported in December of 2016 with 1018 cases reported from multiple regions of Karachi (35). Up to September 2021, according to the European Center for Disease Prevention and Control, in 2021 133,928 cases have been reported (36). Of those, 106,768 from the Americas and the Caribbean (97% from Brazil), 27,056 from Asia (93% from India) and 104 from Africa (all from the Democratic Republic of Congo) (36).

Multiple studies have discovered genetic variants in the immune response to specific pathogens, providing important insights into the genetic control of immune signaling in humans (37). Increasing evidence support the fact that host genetics drives phenotypes of infectious diseases, however a gap still exists in CHIKV infection. A characteristic feature of many human infections is that only a proportion of exposed individuals develop clinical disease (37). Mouse studies have illustrated the potential importance of host genetic effects, by showing differences between different inbred strains in bacterial loads, cytokine responses and outcomes following bacterial and mycobacterial infection (38).

In humans, genetic studies, mainly using genome-wide association studies (GWAS), have discovered genetic variants in the immune response to specific pathogens, highlighting the role of shared host signaling pathways in the pathogenesis of diverse infectious diseases and providing important insights into the genetic control of immune signaling in humans (37). These studies have found correlations between gene polymorphisms with specific phenotypes in infectious diseases. For example, in HIV and AIDS, single nucleotide polymorphisms (SNP) in HLA-C, HLA-B and HCP5 genes were associated with high viral load at set point (39, 40). Also, dengue shock syndrome was associated in Vietnamese patients with SNPs in MICB and PLCE1 genes (41). Regarding CHIKV, few studies have been conducted to elucidate host genetics and specific phenotypes of the disease. The study of the genetic effects of CHIKV infected patients will increase our knowledge and understanding of the pathogenesis of the disease as well as the bases for potential treatment targets. The present review summarizes the current findings on human host genetics and its relationship with immune response in CHIKV infection.

**PATHOGENESIS**

**Innate Immunity**

Acute CHIKV infection elicits robust innate immune responses, leading to elevation of type I IFNs and numerous...
proinflammatory chemokines, cytokines, and growth factors (42–44). Type I IFN signaling controls viral replication and pathogenesis during acute infection (45, 46). In humans, IFN-α appears early in infection and correlates with viral load (42, 47). Coincident with rising viral loads and IFN-α responses, the vast majority of infected patients experience sudden onset of clinical illness, with a small proportion of infected individuals (5–28%) remaining asymptomatic (48).

The mechanism which such immune response is initiated by CHIKV is like other emerging RNA virus infections. In a nutshell, innate immune response starts with recognition of viral RNA by pattern recognition receptors (PRRs). In the case of CHIKV, double stranded RNA (dsRNA) induce toll like receptor (TLR) 3, retinoic acid-inducible gene I (RIG-I) and melanoma differentiation-associated protein 5 (MDA5), while single-stranded RNA (ssRNA) induce TLR-7 (49–52). A signaling cascade is initiated which results in activation of nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) and interferon regulator factors (IRFs) inducing the transcription of interferons and pro-inflammatory cytokines (49–52). See Figure 1 for more detail. The produced type I interferons (IFN α/β) bind to receptors IFNAR1 and 2 (interferon receptor α/β) inducing phosphorylation of Janus kinase 1 (JAK1) and tyrosine kinase 2 (TYK2) which leads to assembly of interferon stimulated gene factor 3 (ISGF3) complex. ISGF3 binds to interferon stimulated genes (ISGs) resulting in gene expression of IFNs (52, 53, 55, 56). As expected, CHIKV developed mechanisms to counteract the host immune response. CHIKV inhibits IFN signaling with its own nsP2 by blocking the JAK/STAT (signal transducer and activator of transcription) signaling pathway (53, 57). Also, CHIKV nsP2 inhibits RNA polymerase II by inducing the degradation of its catalytic subunit RpB1, blocking the expression of cellular genes (53, 58, 59).

**Adaptive Immunity**

Symptoms of acute CHIKV disease are caused by direct cellular damage and local inflammation, but the specific contributions of viral replication and the host immune response to CHIKV infection are yet to be completely unraveled (60). CHIKV infection is cytopathic and induces apoptosis, resulting in direct tissue injury. Numerous cell types, many of which are located at sites of disease, are susceptible to CHIKV, including chondrocytes, endothelial cells, fibroblasts, hepatocytes, macrophages, monocytes, muscle satellite cells, myocytes, and osteoblasts (61–64).

Monocytes and macrophages are targeted by CHIKV and contribute to virus-induced pathogenesis. Activated macrophages are the primary infiltrating cell in infected tissues (65, 66), and elevated levels of MCP-1, the major chemoattractant for monocytes and macrophages, correlate with high viral loads.
in persons with acute CHIKV infection (42–44, 47, 66, 67). A meta-analysis of immune mediators from geographically distinct cohorts revealed an immune mediator signature dominated by proinflammatory cytokines, which include INF-α, INF-γ and IL-2, 2R, 6, 7, 12, 15, 17 and 18 (42).

Acute infection in humans leads to activation and proliferation of CD8+ T cells, while a CD4+T cell response is dominant during the chronic phase of CHIKV disease (68). Although activated, CD8+ T cells do not appear to mediate CHIKV clearance or disease in animals (69). In contrast, studies using mice deficient in various types of lymphocytes implicate CD4+ T cells as inflammatory mediators in infected tissues (70). However, these cells also may contribute to viral clearance (70). Tregs are involved in CHIKV pathology, as expansion of Tregs reduces CHIKV disease by selectively inhibiting CHIKV-specific CD4+ effector T cells (71). In addition, γδ T cells, which are abundant in skin, protect against CHIKV disease, as γδ T cell–deficient mice display exacerbated CHIKV infection (72). Development of CHIKV neutralizing antibodies is essential to control CHIKV viremia (69, 70). In humans, IgM levels are detected within 5–7 days after the onset of symptoms, peak several weeks after infection, and begin to wane over the next several months (14). An IgG response can be detected approximately 7–10 days after onset of illness, often after viremia has been cleared (14).

Studies of CHIKV-infected humans and animals have defined symptoms and immune responses of acute CHIKV infection, but much of the molecular interplay between virus and host remains to be established. To this date, it is unknown why a percentage of patients do not develop clinical symptoms despite having been exposed to the virus and developing an adaptive immune response (presence of positive CHIKV IgM or IgG).

HOST GENETICS AND CHIKUNGUNYA

Human Leukocyte Antigen

Virulence factors specific to the infective agent as well as host factors like innate and adaptive immune response play an important part in disease susceptibility (73–75). Regarding host factors, the HLA plays a major role in initiating immune responses; the HLA type I molecules present pathogen peptides to CD8+ lymphocyte cells, while HLA type II molecules present pathogen peptides to CD4+ lymphocyte cells (76).

HLA molecules are coded on the short arm of chromosome 6, occupying a large portion of the DNA (~3,500 kilobases) (77). To date, HLA molecules are the most polymorphic genes in the human genome (77). These polymorphisms allow the immune system to increase the repertoire of peptides presented by HLA molecules, which in turn will affect the susceptibility to infectious diseases.

Many chronic diseases and their host’s interaction with the disease have been studied to understand their immunogenetics. HLA-DR3 (HLA-DRB1*0301, DQB1*0201) and DR4 (HLA-DRB1*04, DQB1*0302) are markers for type 1 diabetes in Caucasian populations, but not among Japanese patients (78). The DRB1*07 allele is associated with protection against Dengue virus infection in the Cuban population, but not in the Sri Lankan population (79, 80). Studies have demonstrated HLA class II alleles association to susceptibility or resistance to CHIKV (Table 1, Figure 2), however none have reported associations with clinical symptoms of CHIKV infection (78, 81, 82).

A study in 73 Gabonese patients with CHIKV infection, Petitdemange et al. studied the association between killer cell immunoglobulin-like receptors (KIR), their HLA-class I genotype and susceptibility to CHIKV (83). KIR receptors on the surface of natural killer (NK) cells bind to HLA-class I molecules on target cells. The KIR-HLA interaction has a functional significance in response to infectious diseases activating or inhibiting NK cells. The authors found that KIR2DL1 and its interaction with HLA-C2 (KIR2DL1-C2) granted susceptibility to CHIKV infection, while KIR2DS5 conferred protection (83). The authors believe that the expansion of highly functional NK cells and the development of a strong adaptive memory response are associated with the interplay between KIR2DL1 and HLA-C2 in CHIKV infected patients.

In a study of 21 patients from Reunion Island with chronic chikungunya, HLA-DRB1*01 and DBR1*04 alleles were frequently found among the patients who developed rheumatoid arthritis after the infection, indicating the probable involvement of HLA class II gene in chikungunya infection (87). However, details regarding the relevance of these alleles with chikungunya virus associated clinical presentations were not indicated in the study.

In India, two studies have reported the association of HLA alleles with CHIKV infection (78, 81). One study demonstrated the presence of HLA-DRB1*04-HLA-DQB1*03 haplotype with susceptibility to CHIKV infection, and the presence of HLA-DRB1*11 and HLA-DRB1*11-HLA-DQB1*03 haplotype with resistance to the infection (81). According to the authors, one explanation could be that the epitopes presented by HLA-DRB1*11 modulates toward a more robust immune response to CHIKV by means of CD4 T cells.

The other study reported a lower frequency of HLA-DQB1*03:03 allele in CHIKV infected patients with statistical significance when compared to normal subjects (78). The authors suggest that the DQ*03:03 allele may stimulate diverse antiviral CD4 T-cell responses and therefore its association with protection against CHIKV. In this study, although HLA-DRB1*01 and HLA-DRB1*04 were more frequent in CHIKV infected patients, the difference was not statistically significant. In the same study, the presence of non-glutamic acid at position 86 of the peptide binding groove of DQB1genotypes was associated with infection while lower frequencies of glutamic acid at the same position was protective against CHIKV infection when compared with healthy controls. This can be explained by the fact that the presence of glutamate at the 86th position allows for accommodation of peptides with large hydrophobic amino acids, which in turn enhance the ability to bind a large number of amino acids conferring a selective advantage against CHIKV (78, 88). Taking this into account, special interest should be given to research of HLA-DRB1 alleles in CHIKV infected patients and its role in the pathophysiology of the disease.

A study on 65 patients with confirmed CHIKV infection from Colombia demonstrated the presence of five HLA class I and II
| Country | Sample | Gene | Allele/polymorphism | Findings | Type of association | Year | Reference |
|---------|--------|------|----------------------|----------|---------------------|------|-----------|
| India - 101 CHIKV - 104 controls | HLA class II - DQB1 - DRB1 | DQB1*03:03 - *p86 non GLU | 0.13 0.04-0.40 0.024 | Protection against CHIKV | 2013 | (78) |
| India - 100 CHIKV - 250 controls | HLA class II - DRB1 | DRB1*111 | 0.21 0.07-0.61 0.002 | Protection against CHIKV | 2014 | (81) |
| Gabon - 73 CHIKV - 54 controls | KIR HLA class I - C - Bw4 | 2DL1 | NP 0.03-0.17 0.028 | Protection against CHIKV | 2015 | (84) |
| Singapore - 94 CHIKV - 179 controls | TLR-3 | RS2775292 | 2.16 1.31-3.42 0.029 | Protection against CHIKV | 2016 | (85) |
| India - 101 CHIKV - 101 controls | OAS1 OAS2 OAS3 | CD209 *RS4804803 - A-G | 0.16 0.03-0.97 0.037 | Protection against fever | 2017 | (86) |
| India - 173 CHIKV - 157 controls | TLR-3 TLR-7 TLR-8 | TLR-3 *RS775290 | 2.10 1.03-4.30 0.039 | Protection against fever | 2018 | (87) |

(Continued)
### Table 1 | Continued

| Country          | Sample          | Gene    | Allele/polymorphism | Findings                              | Type of association       | Year   | Reference |
|------------------|-----------------|---------|---------------------|---------------------------------------|---------------------------|--------|-----------|
| Colombia         | 65 CHIKV        | HLA-class I | A*29               |                                       | Protection against CHIKV | 2021   | Accepted  |
|                  | 100 controls    |         | B*35               |                                       |                           |        |           |
|                  |                 | A*68    | B*35               |                                       |                           |        |           |
|                  |                 | DRB1    | A*29               |                                       |                           |        |           |
|                  |                 |         | B*35               |                                       |                           |        |           |
|                  |                 | DRB1*01 | A*29               |                                       |                           |        |           |
|                  |                 |         | B*35               |                                       |                           |        |           |
|                  |                 | DRB1*04 | A*29               |                                       |                           |        |           |
|                  |                 |         | B*35               |                                       |                           |        |           |
|                  |                 | DRB1*13 | A*29               |                                       |                           |        |           |
|                  |                 |         | B*35               |                                       |                           |        |           |
|                  |                 | A*68    | B*35               |                                       |                           |        |           |
|                  |                 |         | B*35               |                                       |                           |        |           |
|                  |                 | DRB1*01 | A*68               |                                       |                           |        |           |
|                  |                 |         | B*35               |                                       |                           |        |           |
|                  |                 | DRB1*04 | A*68               |                                       |                           |        |           |
|                  |                 |         | B*35               |                                       |                           |        |           |
|                  |                 | DRB1*13 | A*68               |                                       |                           |        |           |

OR, odds ratio; CI, 95% confidence interval; CHIKV, chikungunya virus infection; HLA, human leukocyte antigen; KIR, killer cell immunoglobulin like receptor; TLR, toll like receptor; OAS, 2′-5′oligoadenylate synthase; †: in females; ‡: in males.

**Figure 2** | Proposed mechanisms of genetic host factors in CHIKV pathogenesis.

alleles in CHIKV infected patients when compared to healthy subjects (accepted). Specifically, HLA-A*68, HLA-B*35, HLA-DRB1*01, HLA-DRB1*04 and HLA-DRB1*13. Of interest, HLA-A*68 and HLA-DRB1*04 had the strongest association with CHIKV infection. In fact, HLA-DRB1*04 was the only allele associated with the presence of rash in the abdomen and the face. No other alleles were statistically associated with other clinical symptoms or disability scores. Only class I alleles (HLA-A*29 and HLA-B*46) were associated with reduced risk of CHIKV infection as well as rash in the abdomen and the face (HLA-B*35). None of the HLA-DRB1 alleles showed protection for CHIKV infection. Studies have found that in HLA-A*68 a valine residue at position 245 replace the alanine present in other HLA molecules (89, 90). This distorts the α3 loop, resulting...
pathogens can trigger autoimmunity by molecular mimicry, autoimmune diseases. The second hypothesis suggests that which could explain the susceptibility to infection in CHIKV infected patients, the progression to AIDS was associated with CD8-T cells, in a less energetically favorable interaction with CD8-T cells, which could explain the susceptibility to infection in CHIKV patients. On the other hand, HLA-A*29 distinguishes from other HLA-A alleles by the presence of leucine at position 62 and glutamine at position 63 (91). This change in position 63 has the largest effect on the ability to bind antigenic peptides in the peptide binding groove of HLA-A (91). In fact, the 62–63 motif may influence the flexibility to accommodate antigenic peptides, which can confer selective advantage against CHIKV (91). In another study in human immunodeficiency virus (HIV) infected patients, the progression to AIDS was associated with the presence of HLA-B*35-HLA-Cw4 haplotype due to reduction of natural killer cell number and activity (92). A finding that could explain the susceptibility to CHIKV infection in our population. In our population, HLA-B*46 was associated with protection against CHIKV infection. HLA-B*46 is an unusual allele formed by the recombination between HLA-B*15 and HLA-C*01, which allows it to interact with KIR ligand (93). Its distinctive peptide-binding site derived from its recombination and ability to react with KIR ligands helps create a strong KIR cell mediated immune response, which in turn could explain its protection against CHIKV infection. Regarding HLA class II alleles, HLA-DRB1*01 and *04, which were associated with susceptibility to CHIKV in our population, were also found in parvovirus B19 infection by Kerr et al. (94). It is known that both DRB1*01 and *04 code for the shared epitope in residues 70 to 74 in the HLA-DRB chain (95). We hypothesize that CHIKV antigens could bind the shared epitope triggering innate immune signaling as well as production of pro-inflammatory cytokines like IL-6, TNF-α and IL-23 by dendritic cells, conferring symptomatic susceptibility to CHIKV infection. Finally, HLA-DRB1*13 has been associated with carrying an asparagine in position 37 of P9 peptide binding pocket granting electropositivity (96). This restricts the range of peptides that can be presented which is sufficient to alter recognition by the T-cell receptor, and therefore increase susceptibility to CHIKV infection.

The relationship between host genetics and disease can be variable. The presence of an allele like HLA-DRB1*13 is associated with CHIKV infection (susceptibility), on the other hand, the same allele confers protection for AIH. On the contrary, while HLA-A*29 and B*46 protect against CHIKV infection, they are associated with birdshot retinochoroidopathy and severe sacroiliitis in psoriatic arthritis, respectively. To explain the relationships between HLA variants involved in both autoimmune and infectious diseases, two hypotheses have been proposed (97). The first hypothesis states that pressure on the human genome by pathogens has led to selection of host defense genes that protects against infections. However, this advantageous selection may also increase the risk of developing autoimmune diseases. The second hypothesis suggests that pathogens can trigger autoimmunity by molecular mimicry, epitope spreading bystander activation or cryptic antigens (98).

**Candidate Genes**

Genes outside the HLA complex have been studied in CHIKV infection (Table 1, Figure 2). Specifically, polymorphisms of TLR genes as well the 2′-5′-oligoadenylate synthetase (OAS) gene cluster and CD209. As mentioned before, it is well-established that the innate immune response starts with recognition of viral RNA genome by PRRs. In the case of CHIKV infection, its RNA is recognized by TLRs (3, 7 and 8), retinoic acid-inducible gene I (RIG-1) like receptors (RLRs) and melanoma differentiation-associated protein 5 (MDA5) (99). The PRRs stimulates the production of pro-inflammatory cytokines through myeloid differentiation factor 88 (MyD88) and TRAF, which in turn activates OAS genes increasing viral degradation (62). TLR-3 polymorphisms can change the ecto-domain of the receptor altering the ligand-receptor interaction, while TLR-7 polymorphisms affects TLR-7 processing and receptor expression (100–102). Studies on TLR-8 polymorphisms have demonstrated variation in transcription of TLR-8 isoforms which affects NF-κB activation as well as diverse production of TNF-α and IL-1β (103, 104).

A study found the SNP rs6552950 in the TLR-3 gene to be associated with disease severity and CHIKV-specific neutralizing antibody response and the SNP rs3775292 to disease susceptibility (84). In this study the authors demonstrated that the polymorphisms in TLR-3 gene produced a loss in TLR-3 functionality which decreased the production of anti-E2EP3 IgG anti-bodies (CHIKV specific neutralizing antibodies), reducing CHIKV clearance and eliciting severe disease (defined by maximum temperature >38.5°C, a maximum pulse rate >100 beats/min or a nadir platelet count <100 x 10^9/l).

Similarly, another study found three polymorphisms of TLR-7 (rs179010, rs5741880, rs38533839) and one of TLR8 (rs3764879) to be significantly associated with CHIKV infection (86). In the same study, the SNP rs3775290 from the TLR-3 gene was associated with the presence of joint pain, the SNPs rs179010, rs5741880 and rs38533839 from the TLR-7 gene with fever, joint pain, and rash, respectively. Interestingly, the SNP in the TLR-7 gene associated with fever (rs179010) was also present in patients with CHIKV infection and increased levels of IFN-α. Finally, fever was also associated with a SNP (rs3764880) in the TLR-8 gene. Studies have found that polymorphisms in TLR-7 increases B-cell sensitivity to RNA-containing autoantigens in the development of systemic autoimmune. Specifically, rs3853389 of TLR-7 in lupus patients was associated with skin involvement like malar rash and photosensitivity (105). Also, TLR-7 and −8 polymorphisms may impair the immune response to hepatitis C virus due to less INF-α (103). Other studies have demonstrated that TLR-8 polymorphisms could produce a truncated TLR-8 with a shorter signal peptide which result in a more rapid decay of TLR-8 or may affect the protein function impairing NF-κB activation in-vitro (106, 107).

The OAS gene cluster and CD209 (also known as DC-SIGN: dendritic cell-specific intercellular adhesion molecule-3-grabbing non-integrin) has also been studied in CHIKV infected patients. OAS activation by INFs degrades viral RNA decreasing viral replication, while the DC-SIGN, a type II transmembrane in macrophages and dendritic cells plays an important role in innate immunity activation through recognition of high-mannose type N-glycans pathogen associated molecular patterns (PAMPs) (108–111). A study in India found that the rs4804803 of the CD209 gene is associated with susceptibility to CHIKV infection.
infection (85). The researchers also found that the same polymorphism (rs4804803) and others from de OAS gene cluster (OAS1 rs1131454, OAS2 rs1732778 and rs15895, and OAS3 rs2285932) influence the risk of developing clinical symptoms in CHIKV infected patients. The authors hypothesize that some OAS polymorphisms reduce the activity of the OAS system, decreasing inflammatory response which could protect against developing symptoms. On the other hand, other OAS polymorphisms increase antiviral activity, reducing viral replication and therefore protecting against developing symptoms. Also, the authors believe that CD209 polymorphisms affect binding of transcription factors and the presence of G-G polymorphism influence the expression of DC-SIGN, all of which at end affects the innate and adaptive immune response of dendritic cells increasing susceptibility to CHIKV infection. Conversely, G-A polymorphisms of CD209 decreases inflammatory response which could explain its association with protection against fever.

CONCLUSION

Increasing evidence support the fact that host genetics drives phenotypes of infectious diseases, however a gap still exists in CHIKV infection. So far it has been shown that the presence of certain alleles in certain populations as well as polymorphisms in certain genes change the presentation and course of the disease. However, some important questions remain unanswered. Why some patients develop symptoms, while others do not regardless of being infected? Why some patients develop chronic symptoms? Why the host immune system responds differently to the same infectious agent? Is there a genetic predisposition to host-agent interaction? Questions that can be applied not only to CHIKV but to other infectious diseases. The door remains open for research to provide a newer insight in the host dynamics and infectious diseases, especially, by conducting association studies between inflammatory markers, clinical manifestations, with long-term follow-up are necessary to understand the repercussions that host genetic factors have on the immune response and how this is reflected in the clinical picture of the infection both acutely and chronically. Additionally, the possibility of conducting genetic studies that include not only candidate genes and HLA alleles using genome wide analysis or exome wide analysis techniques in conjunction with proteomic techniques will allow us to find possible associations that at first glance were not on the radar of the pathogenesis of the disease. The study of the genetic effects of CHIKV infected patients will increase our knowledge and understanding of the pathogenesis of the disease as well as the bases for potential treatment targets.

AUTHOR CONTRIBUTIONS

JR, MA-B, AS, DM-A, CV-E, VR, SB-M, IP-B, MC, and JL: conceptualization, supervision, funding acquisition, methodology, data curation, writing-original draft preparation, and writing-review and editing. All authors contributed to the article and approved the submitted version.

FUNDING

The study was supported by the Colombian Rheumatology Association (ASOREUMA) under grant number Acta 169 10th July 2015; Universidad de La Sabana under grant number MED-197-2015; and COLCIENCIAS doctoral scholarship under grant number 757-2016.

REFERENCES

1. Powers AM, Brault AC, Tesh RB, Weaver SC. Re-emergence of chikungunya and o’nyong-nyong viruses: evidence for distinct geographical lineages and distant evolutionary relationships. J Gen Virol. (2000) 81:471–9. doi: 10.1099/0022-1317-81-2-471
2. Powers AM, Logue CH. Changing patterns of chikungunya virus re-emergence of a zoonotic arbovirus. J Gen Virol. (2007) 88:2363–77. doi: 10.1099/vir.0.82858-0
3. Enserink M. Infectious diseases. Massive outbreak draws fresh attention to little-known virus. Science. (2006) 311:1085. doi: 10.1126/science.311.5764.1085a
4. Khan AH, Morita K, Parquet MDC, Hasebe F, Mathenge EGM, Igarashi A. Complete nucleotide sequence of chikungunya virus and evidence for an internal polyadenylation site. J Gen Virol. (2002) 83:3075–84. doi: 10.1099/0022-1317-83-12-3075
5. Thiberville S-D, Moyen N, Dupuis-Maguiraga L, Nougairede A, Gould EA, Roques P, et al. Chikungunya fever: epideemiology, clinical syndrome, pathogenesis and therapy. Antiviral Res. (2013) 99:345–70. doi: 10.1016/j.antiviral.2013.06.009
6. Voss JE, Vaney MC, Duquerroy S, Vonrhein C, Girard-Blanc C, Crublet E, et al. Glycoprotein organization of chikungunya virus particles revealed by X-ray crystallography. Nature. (2010) 468:709–12. doi: 10.1038/nature09555
7. Simizu B, Yamamoto K, Hashimoto K, Ogata T. Structural proteins of chikungunya virus. J Virol. (1984) 51:254–8. doi: 10.1128/jvi.51.1.254-258.1984
8. Silva LA, Dermody TS. Chikungunya virus: epidemiology, replication, disease mechanisms, and prospective intervention strategies. J Clin Invest. (2017) 127:737–49. doi: 10.1172/JCI84417
9. Hua C, Combe B. Chikungunya virus-associated disease. Curr Rheumatol Rep. (2017) 19:69. doi: 10.1007/s11926-017-0694-0
10. Vu DM, Jungkind D, LaBeaud AD. Chikungunya virus. Clin Lab Med. (2017) 37:371–82. doi: 10.1016/j.clinlab.2017.01.008
11. Grivard P, Le Roux K, Laurent P, Fianu A, Perrau J, Gigan J, et al. Molecular and serological diagnosis of chikungunya virus infection. Pathol Biol. (2007) 55:490–4. doi: 10.1016/j.patbio.2007.07.002
12. Chelluboina S, Robin S, Aswatharaj S, Arunkumar G. Persistence of antibody response in chikungunya. Viruses. (2019) 11:20–73. doi: 10.1007/s13357-019-03534-5
13. Pierro A, Rossini G, Gaibani P, Finarelli AC, Moro ML, Landini MP, et al. Persistence of anti-chikungunya virus-specific antibodies in a cohort of patients followed from the acute phase of infection after the 2007 outbreak in Italy. New Microbes New Infect. (2015) 7:23–5. doi: 10.1016/j.nmni.2015.04.002
14. Kam YW, Simarmata D, Chow A, Her Z, Teng TS, Ong EKS, et al. Early appearance of neutralizing immunoglobulin G3 antibodies is associated with chikungunya virus clearance and long-term clinical protection. J Infect Dis. (2012) 205:1147–54. doi: 10.1093/infdis/jis333
15. Tsetsarkin KA, Vanlandingham DL, McGee CE, Higgs S. A single mutation in chikungunya virus affects vector specificity and epidemic potential. PLoS Pathog. (2007) 3:1895–906. doi: 10.1371/journal.ppat.0030201
24. Tsetsarkin KA, Weaver SC. Sequential adaptive mutations enhance efficient transmission of chikungunya virus. *J Virol.* (2010) 84:497–504. doi: 10.1128/JVI.01603-09

25. Tsetsarkin KA, Chen R, Yun R, Rossi SL, Plante KS, Guerbois M, et al. Tracking epidemic chikungunya virus into the Indian Ocean from East Africa. *J Gen Virol.* (2008) 89:2754–60. doi: 10.1099/vir.0.0085413-0

26. Rezza G, Nicoletti L, Angelini R, Romi R, Finarelli A, Panning M, et al. Genome-wide association study identifies susceptibility loci for dengue shock syndrome at MHC and PLCe1. *Nat. Genet.* (2011) 43:1139–41. doi: 10.1038/ng.960

27. Njenga MK, Nderitu L, Ledermann JP, Ndirangu A, Logue CH, Kelly CHL, et al. Multi-peak adaptive landscape for chikungunya virus evolution predicts continued fitness optimization in *Aedes albopictus* mosquitoes. *Nat Commun.* (2014) 5:4084. doi: 10.1038/ncomms5084

28. Hapuarachchi HC, Bandara KBAT, Sumanadasa SDM, Hapugoda MD, Lai AI, Cassadou S, Boucau S, Petit-Sinturel M, Huc P, Leparc-Goffart I, Ledrans M. Emergence of chikungunya virus on the French Polynesia. *J Hyg.* (2015). doi: 10.1016/j.jhyg.2015.04.016

29. Nhan TX, Musso D. The burden of chikungunya in the Pacific. *Clin Microbiol Rev.* (2011) 24:126–52. doi: 10.1128/CMR.00029-10

30. Dupont-Rouzeyrol M, Caro V, Guillaumot L, Vazeille M, D’Ortenzio E, De Lamberville PA. Tracking epidemic chikungunya virus into the Indian Ocean from East Africa. *J Gen Virol.* (2008) 89:2754–60. doi: 10.1099/vir.0.0085413-0

31. Cassadou S, Boucau S, Petit-Sinturel M, Huc P, Leparc-Goffart I, Ledrans M. Emergence of chikungunya fever on the French Polynesia. *Euro Surveill.* (2014) 19:20752. doi: 10.2807/1560-7917.ES2014.19.13.20752

32. The Pan American Health Organization. *Number of Reported Cases of Chikungunya Fever in the Americas, by Country or Territory Cumulative Cases. Data Source : Cases Reported by IHR NFpS to PAHO / WHO and / or Through Member States Websites or Official News Publication (2015).* Available online at: https://www.paho.org/hq/index.php?option=com_content&view=article&id=5927&Itemid=40931&lang=en (accessed May 15, 2015).

33. Cunha MS, Costa PAG, Correa IA, de Souza MMM, Calil PT, da Silva GPD, et al. Chikungunya virus: an emergent arbovirus to the South American Continent and a continuous threat to the world. *Front Microbiol.* (2020) 11:1297. doi: 10.3389/fmicb.2020.01297

34. Translational Research Consortia (TRC) for Chikungunya Virus in India. Current status of chikungunya in India. *Front Microbiol.* (2021) 12:695173. doi: 10.3389/fmicb.2021.695173

35. Ali I, Dasti JI. Chikungunya virus: an emerging arbovirus in Pakistan. *J Pak Med Assoc.* (2018) 68:252–7.

36. European Centre for Disease Prevention and Control and European Food Safety Authority. *Chikungunya Worldwide Overview.* Available online at: https://www.ecdc.europa.eu/en/chikungunya-monthly (accessed October 19, 2021).

37. Chapman SJ, Hill AVS. Human genetic susceptibility to infectious disease. *Nat Rev Genet.* (2012) 13:75–88. doi: 10.1038/nrg3114

38. Gingles NA, Alexander JE, Kadioglu A, Andrew PW, Kerr A, Mitchell TJ, et al. Role of genetic resistance in invasive pneumococcal infection: identification and study of susceptibility and resistance in inbred mouse strains. *Infect Immun.* (2001) 69:426–34. doi: 10.1128/IAI.69.1.426-434.2001

39. Fellay J, Ge D, Shanna KV, Kolombo S, Ledergerber B, Cirulli ET, et al. Common genetic variation and the control of HIV-1 in humans. *PLoS Genet.* (2009) 5:e1000791. doi: 10.1371/journal.pgen.1000791

40. Fellay J, Shanna KV, Ge D, Kolombo S, Ledergerber B, Weale M, et al. A whole-genome association study of major determinants for host control of HIV-1. *Science.* (2007) 317:944–7. doi: 10.1126/science.1143767

41. Khor CC, Chau TNR, Pang J, Davila S, Long HT, Ong RTH, et al. Genome-wide association study identifies susceptibility loci for dengue shock syndrome at MHC and PLCe1. *Nat. Genet.* (2011) 43:1139–41. doi: 10.1038/ng.960

42. Teng T-S, Kam Y-W, Lee B, Hapuarachchi HC, Wimal A, Ng L-C, et al. A systematic meta-analysis of immune signatures in patients with acute chikungunya virus infection. *J Infect Dis.* (2015) 211:1925–35. doi: 10.1093/infdis/jiv049

43. Ruiz Silva M, van der Ende-Metselaar H, Muldomen-Rybiert IA. Mechanism and role of MCP-1 upregulation upon chikungunya virus infection in human peripheral blood mononuclear cells. *Sci Rep.* (2016) 6:32288. doi: 10.1038/srep32288

44. Her Z, Malleret B, Chan M, Ong EKS, Wong SC, Kwek DJC, et al. Active infection of human blood monocytes by chikungunya virus triggers an innate immune response. *J Immunol.* (2010) 184:5903–13. doi: 10.4049/jimmunol.0904181

45. Couderc T, Leucit M. Chikungunya virus pathogenesis: from bedside to bench. *Antiviral Res.* (2015) 121:120–31. doi: 10.1016/j.antiviral.2015.07.002

46. Gardner CL, Burke CW, Higgs ST, Klimstra WB, Ryman KD. Interferon-alpha/beta deficiency greatly exacerbates arthritogenic disease in mice infected with wild-type chikungunya virus but not with the cell culture-adapted live-attenuated 181/25 vaccine candidate. *Virology.* (2012) 425:103–12. doi: 10.1016/j.virol.2011.12.020

47. Chow A, Her Z, Ong EKS, Chen J, Dimataf M, Kwek DJC, et al. Persistent arthragia induced by Chikungunya virus infection is associated with interleukin-6 and granulocyte macrophage colony-stimulating factor. *J Infect Dis.* (2011) 203:149–57. doi: 10.1093/infdis/ijq042

48. Dupuis-Maguiraga L, Noret M, Brun S, Le Grand R, Gras G, Roques P. Chikungunya disease: infection-associated markers from the acute to the chronic phase of arbovirus-induced arthralgia. *PLoS Negl Trop Dis.* (2012) 6:e1446. doi: 10.1371/journal.pntd.0001446

49. Jensen S, Thomsen AR. Sensing of RNA viruses: a review of innate immune receptors involved in recognizing RNA virus invasion. *J Virol.* (2012) 86:2900–10. doi: 10.1128/JVI.05738-11

50. Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. *Cell.* (2006) 124:783–801. doi: 10.1016/j.cell.2006.02.015

51. Dias Junior AG, Sampaio NG, Rehwinkel J. A balancing act: MDAS in antiviral immunity and autoinflammation. *Trends Microbiol.* (2019) 27:75–85. doi: 10.1016/j.tim.2018.08.007

52. Nelemans T, Kikkert M. Viral innate immune evasion and the pathogenesis of emerging RNA virus infections. *Viruses.* (2019) 11:961. doi: 10.3390/v11090961

53. Valdés López JF, Verilla PA, Urcuequi-Inchima S. Chikungunya virus and Zika virus, two different viruses examined with a common aim: role of pattern recognition receptors on the inflammatory response. *J Interf Cytokine Res.* (2019) 39:507–21. doi: 10.1089/jirc.2019.0058
54. Han J. Myd88 beyond toll. Nat Immunol. (2006) 7:370–1. doi: 10.1038/nijm3406-370
55. McNab F, Mayer-Barber K, Sher A, Wack A, O’Garra A. Type I interferons in infectious disease. Nat Rev Immunol. (2015) 15:87–103. doi: 10.1038/nrd3787
56. Levy DE, Marie IJ, Durbin JE. Induction and function of type I and III interferon in response to viral infection. Curr Opin Virol. (2011) 1:476–86. doi: 10.1016/j.coviro.2011.11.001
57. Fros JJ, Liu WJ, Prow NA, Geertsema C, Ligtenberg M, Vanlandschoot M, et al. Chikungunya virus nonstructural protein 2 inhibits type I/II interferon-stimulated JAK-STAT signaling. J Virol. (2010) 84:10877–87. doi: 10.1128/JVI.00949-10
58. Akhrymuk I, Kulemzin SV, Frolova EI. Evasion of the innate immune response factors 3 and 7 protect against chikungunya virus hemorrhagic fever and shock. J Virol. (2012) 86:9888–98. doi: 10.1128/JVI.00956-12
59. Hawman DW, Stoermer KA, Montgomery SA, Pal P, Oko L, Diamond NE. Interferon response to viral infection with an epidemic strain of chikungunya virus. PLoS ONE. (2011) 6:e18096. doi: 10.1371/journal.pone.0018096
60. Dhanwani R, Khan M, Alam SI, Rao PVL, Parida M. Differential protein kinase R-independent translational shutoff. J Virol. (2012) 86:7180–91. doi: 10.1128/JVI.00541-12
61. White LJ, Sali T, Alvarado D, Gatti E, Pierre P, Streblov D, et al. Chikungunya virus induces IPS-1-dependent innate immune activation and protein kinase R-independent translational shutoff. J Virol. (2011) 85:606–20. doi: 10.1128/JVI.00767-10
62. Dhanwani R, Khan M, Alam SI, Rao PVL, Parida M. Differential proteome analysis of chikungunya virus-infected newborn mice tissues reveal implication of stress, inflammatory and apoptotic pathways in disease pathogenesis. Proteomics. (2011) 11:1936–51. doi: 10.1002/pmic.201000500
63. Ziegler SA, Lu L, da Rosa APAT, Xiao S-Y, Tesh RB. An animal model for studying the pathogenesis of chikungunya virus infection. Am J Trop Med Hyg. (2008) 79:133–9. doi: 10.4269/ajtmh.2008.79.133
64. Rohatgi A, Corbo JC, Monte K, Higgs S, Vanlandingham DL, et al. Chikungunya virus induces Rpb1, a catalytic subunit of RNA polymerase II. J Virol. (2012) 86:2414–25. doi: 10.1128/JVI.02716-13
65. Ozden S, Huere M, Riviere J-P, Coffey LL, Afonso PV, Mouly V, et al. Infection of myofibers contributes to increased pathogenicity during chikungunya virus infection. J Virol. (2013) 87:6862–72. doi: 10.1128/JVI.00364-13
66. Wu SY, Rueda PA, Gardner J, Wilson JAC, Larcher T, Colle M-A, et al. Functional and biophysical characterization of an HLA-Aw68 ligand. Cell Rep. (2017) 19:1394. doi: 10.1016/j.celrep.2017.04.059
67. Wauquier N, Becquart P, Nkoghe D, Padilla C, Ndjoyi-Mbiguin A, Leroy E, et al. Multiple immune factors are involved in controlling acute and chronic chikungunya virus infection. EMBO J. (2010) 29:4600–13. doi: 10.1002/ebony.201004649
68. Bouquillard E, Combe B. Rheumatoid arthritis after chikungunya fever: a mean follow-up of two years. J Bone Spine. (2009) 76:654–7. doi: 10.1016/j.jbspin.2009.08.005
69. Pettidemange C, Waququier N, Jacquet J-M, Theodorou I, Leroy E, Viellard V. Association of HLA class-I and inhibitory KIR genotypes in gabonese patients infected by chikungunya or dengue type-2 viruses. PLoS ONE. (2014) 9:e108798. doi: 10.1371/journal.pone.0108798
70. Han J. Myd88 beyond tol. Nat Immunol. (2006) 7:370–1. doi: 10.1038/nijm3406-370
71. Kuiper JJW, Venema WJ. HLA-A29 and birdshot uveitis: a distinctive peptidome that includes KIR2DL3 ligands. Cell Rep. (2017) 19:1394. doi: 10.1016/j.celrep.2017.04.059
72. Assunção-Miranda I, Cruz-Oliveira C, Da Poian AT. Molecular mechanisms involved in the pathogenesis of alpavirus-induced arthritis. Biomed Res Int. (2013) 2013:1–11. doi: 10.1155/2013/973516
73. Kam YW, Ong EKS, Rênia L, Tong JC, Ng LFP. Immuno-biology of chikungunya and implications for disease intervention. Microbes Infect. (2009) 11:1186–96. doi: 10.1016/j.micinf.2009.09.003
74. Han J. Myd88 beyond tol. Nat Immunol. (2006) 7:370–1. doi: 10.1038/nijm3406-370
75. Kam YW, Ong EKS, Rênia L, Tong JC, Ng LFP. Immuno-biology of chikungunya and implications for disease intervention. Microbes Infect. (2009) 11:1186–96. doi: 10.1016/j.micinf.2009.09.003
76. Alberts B, Tafuro S, Laugel M, et al. The intergenic recombinant HLA-B*46:01 has a distinctive peptidome that includes KIR2DL3 ligands. Cell Rep. (2017) 19:1394. doi: 10.1016/j.celrep.2017.04.059
Rueda et al.

94. Kerr JR, Matthey LD, Thomson W, Poulton KV, Ollier WER. Association of symptomatic acute human parvovirus B19 infection with human leukocyte antigen class I and II alleles. J Infect Dis. (2002) 186:447–52. doi: 10.1086/341947

95. Gregersen PK, Silver J, Winchester RJ. The shared epitope hypothesis. An approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis. Arthritis Rheum. (1987) 30:1205–13. doi: 10.1002/art.1780301102

96. Hov JR, Kosmiloius V, Traherne JA, Olsson M, Boberg KM, Bergquist A, et al. Electrostatic modifications of the human leukocyte antigen-DP9 peptide-binding pocket and susceptibility to primary sclerosing cholangitis. Hepatology. (2011) 53:1967–76. doi: 10.1002/hep.24299

97. Matsuara V, Kumar V, Wijmenga C, Zhermakova A. The MHC locus and genetic susceptibility to autoimmune and infectious diseases. Genome Biol. (2017) 18:76. doi: 10.1186/s13059-017-1207-1

98. Ercolini AM, Miller SD. The role of infections in autoimmune disease. Clin Exp Immunol. (2009) 155:1–15. doi: 10.1111/j.1365-2249.2008.03834.x

99. Schilte C, Couderc T, Chretien F, Sourisseau M, Gangneux N, Guivel-Bennahmias F, et al. Type I IFN controls chikungunya virus via its action on nonhematopoietic cells. J Exp Med. (2010) 207:429–42. doi: 10.1084/jem.20090851

100. Gao Y, Guo J, Zhang F, Guo Z, Zhang LR, Wang T, et al. Evaluation of neonatal toll-like receptors 3 (c.1377C/T) and 9 (G2848A) gene polymorphisms in HBV intrauterine transmission susceptibility. J Viral Hepat. (2011) 18:1367–75. doi: 10.1111/j.1365-2133.2011.01190.x

101. Kawasaki A, Furukawa H, Kondo Y, Ito S, Hayashi T, Kusaoi M, et al. Electrostatic modifications of the human leukocyte antigen-DR P9 peptide-binding pocket and susceptibility to primary sclerosing cholangitis. Hepatology. (2011) 53:1967–76. doi: 10.1002/hep.24299

102. Matsuara V, Kumar V, Wijmenga C, Zhermakova A. The MHC locus and genetic susceptibility to autoimmune and infectious diseases. Genome Biol. (2017) 18:76. doi: 10.1186/s13059-017-1207-1

103. Wang C-H, Chang SW, Wu YJL, Lin JC, Ho HH, Chou TC, et al. Genetic variations in toll-like receptors (TLRs 3/7/8) are associated with systemic lupus erythematosus in a Taiwanese population. Sci Rep. (2014) 4:3792. doi: 10.1038/srep03792

104. Gantier MP, Irving AT, Kaparakis-Liaskos M, Xu D, Evans VA, Cameron PU, et al. Genetic modulation of TLR8 response following bacterial phagocytosis. Hum Mutat. (2010) 31:1069–79. doi: 10.1002/humu.21321

105. Oh DY, Taube S, Hamouda O, Kücherer C, Poggensee G, Jessen H, et al. A functional toll-like receptor 8 variant is associated with HIV disease restriction. J Infect Dis. (2008) 198:701–9. doi: 10.1086/590431

106. Silverman RH. Viral encounters with 2′,5′-oligoadenylate synthetase and RNase L during the interferon antiviral response. J Virol. (2007) 81:12720–9. doi: 10.1128/JVI.01471-07

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Rueda, Arcos-Burgos, Santos, Martin-Arsanios, Villota-Erazo, Reyes, Bernal-Macias, Peláez-Ballestas, Cardiel and Londeno. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.